Last reviewed · How we verify
Targeted CEA CAR-T
Targeted CEA CAR-T is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd. It is currently in Phase 1 development.
Targeted CEA CAR-T is being studied as a potential treatment for various types of cancer, including advanced lung cancer, peritoneal metastases from colorectal cancer, solid tumor, lung cancer, and colorectal cancer. According to ClinicalTrials.gov, Targeted CEA CAR-T is a type of immunotherapy that involves using CEA-targeted CAR-T cells to target cancer cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Targeted CEA CAR-T |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (PHASE1)
- A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors (PHASE1)
- CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases (PHASE1)
- CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors (PHASE1)
- Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer (PHASE1)
- Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer (PHASE1)
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (PHASE1)
- Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Targeted CEA CAR-T CI brief — competitive landscape report
- Targeted CEA CAR-T updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI
Frequently asked questions about Targeted CEA CAR-T
What is Targeted CEA CAR-T?
Who makes Targeted CEA CAR-T?
What development phase is Targeted CEA CAR-T in?
Related
- Manufacturer: Chongqing Precision Biotech Co., Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing